Cargando…
The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer
This review examines the evolution of the radionuclide diagnosis of HER2-positive breast cancer using various compounds as a targeting module in clinical practice: from full-length antibodies to a new group of small synthetic proteins called alternative scaffold proteins. This topic is of especial r...
Autores principales: | Bragina, O. D., Deyev, S. M., Chernov, V. I., Tolmachev, V. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
A.I. Gordeyev
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307982/ https://www.ncbi.nlm.nih.gov/pubmed/35923562 http://dx.doi.org/10.32607/actanaturae.11611 |
Ejemplares similares
-
Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors
por: Vorobyeva, Anzhelika, et al.
Publicado: (2018) -
Direct Intra-Patient Comparison of Scaffold Protein-Based Tracers, [(99m)Tc]Tc-ADAPT6 and [(99m)Tc]Tc-(HE)(3)-G3, for Imaging of HER2-Positive Breast Cancer
por: Bragina, Olga, et al.
Publicado: (2023) -
Phase I Trial of (99m)Tc-(HE)(3)-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer
por: Bragina, Olga, et al.
Publicado: (2022) -
(131)I-Labeled Anti-HER2 Nanobody for Targeted Radionuclide Therapy of HER2-Positive Breast Cancer
por: Zhao, Lingzhou, et al.
Publicado: (2023) -
Phase I clinical evaluation of (99m)Tc-labeled Affibody molecule for imaging HER2 expression in breast cancer
por: Bragina, Olga, et al.
Publicado: (2023)